Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.
Wednesday, June 19, 2024
Dr. Minal Barve
Click the above link to view the abstract and video; login is required to view the video.
Related Posts
Discover more posts like this.